RTP Mobile Logo
Dissecting the Decision: Documenting and Discussing the Clinical Practice Patterns of Hematologic Oncology Investigators in the Management of Follicular Lymphoma
Released August 2018

Proceedings from Part 1 of a 3-part satellite symposia series during the 2018 Pan Pacific Lymphoma Conference. Featuring perspectives from Drs Stephen M Ansell, Nathan H Fowler, Laurie H Sehn and Andrew D Zelenetz. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of follicular lymphoma (FL).

    OVERVIEW OF ACTIVITY
    FL is an indolent form of non-Hodgkin lymphoma that can vary significantly in its clinical presentation. As such, no single standard approach to the initial management of the disease has been established, and available options range from watchful waiting, radiation therapy and rituximab monotherapy to various combinations of chemoimmunotherapy. In general, the decision to employ one of these approaches versus another is made based on a number of established criteria as well as patient preferences. Despite active treatment in the up-front setting, FL remains incurable, and as patients relapse it becomes more difficult to treat their disease, as durability and duration of response to therapy tend to diminish over time. Notably, recent data sets and corresponding FDA actions have ushered in an era in which additional evidence-based options must now be considered. Thus, a significant need exists to ensure that clinicians and patients are made aware of the risks and benefits associated with all available therapeutic options so that they may make informed and personalized treatment choices.

    These proceedings from a CME/CNE symposium held during the 2018 Pan Pacific Lymphoma Conference use an innovative strategy to formally document and present the perspectives, experiences and preferred treatment approaches of 25 lymphoma-specific investigators. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of FL with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Explore the self-reported practice patterns employed by lymphoma clinical investigators, and apply this knowledge to the diagnosis and treatment of patients with FL.
    • Recognize emerging research data and recent FDA authorizations when designing an optimal therapeutic approach for patients with newly diagnosed FL requiring active therapy.
    • Appreciate emerging Phase III data with rituximab/lenalidomide as front-line treatment for patients with FL, and assess investigator perspectives on the current utility of this novel therapeutic approach in the nonresearch management of previously untreated and relapsed/refractory FL.
    • Individualize the use of maintenance therapeutic approaches in the care of patients with previously untreated FL who have completed induction chemoimmunotherapy.
    • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with relapsed/refractory FL.
    • Develop practical strategies to prevent, recognize and/or ameliorate the toxicities associated with therapies routinely used in the management of FL.
    • Identify ongoing clinical trials evaluating innovative investigational approaches for FL, and obtain consent from appropriate patients for study participation.

    CME/CNE ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education (UNMC CCE), University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) and Research To Practice.

    PHYSICIANS: The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 2.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NURSES: The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    This activity is provided for 2.25 contact hours under ANCC criteria.

    FOR SUCCESSFUL COMPLETION
    CME: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/Lymphomas18/FL/CME.

    CNE: This CNE activity consists of a video component. To receive credit, the participant should review the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/Lymphomas18/FL/CNE.

    CONTENT VALIDATION AND DISCLOSURES
    It is the policy of the UNMC CCE and UNMC CON CNE to ensure balance, independence, objectivity and scientific rigor in all their educational symposia. All faculty, planners and managers participating in these activities are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME/CNE about the products or services of the commercial interest. UNMC CCE, UNMC CON CNE and Research To Practice ensured that any conflicts of interest were resolved before the educational activity occurred.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Stephen M Ansell, MD, PhD
    Professor of Medicine
    Division of Hematology
    Mayo Clinic
    Rochester, Minnesota

    Clinical Trials: Affimed, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc, Takeda Oncology, Trillium Therapeutics Inc.

    Nathan H Fowler, MD
    Co-Director of Clinical and Translational Research
    Lead, Phase I and Indolent Research Groups
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee and Contracted Research: AbbVie Inc, Celgene Corporation, Janssen Biotech Inc, Roche Laboratories Inc.

    Laurie H Sehn, MD, MPH
    Centre for Lymphoid Cancer
    BC Cancer Agency and University of British Columbia
    Vancouver, British Columbia, Canada

    Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Janssen Biotech Inc, Lundbeck, Roche Laboratories Inc, Seattle Genetics, Takeda Oncology.

    Andrew D Zelenetz, MD, PhD
    Medical Director, Medical Informatics
    Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: Adaptive Biotechnologies, Amgen Inc, Celgene Corporation, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Novartis, Roche Laboratories Inc; Contracted Research: Gilead Sciences Inc, MEI Pharma, Roche Laboratories Inc; Data Monitoring Committee: BeiGene.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME/CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and the UNMC CCE do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc, Celgene Corporation and Genentech.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2018
    Expiration date: August 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):